2025-06-10
minor
Study Identification, Study Status, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility v1
Start date2025-06-15→2025-08-01
Enrollment target27→26
InterventionsIparomlimab and Tuvonralimab (QL1706) (Drug), Partial hepatectomy (Procedure), TACE (Procedure)→Iparomlimab and Tuvonralimab (QL1706) (Drug), Partial hepatectomy (Procedure)
Eligibility criteria-45 characters
[...] e criteria for resectable HCC with High Risk of Recurrence:
Tumor diameter >5cm or multipleMultiple (≥32) tumors.
Segmental portal vein invasion (Vp1/Vp2).
CT/MRI imaging: gross classification: infiltrativetype typeII, typeIII, ⅣIV.
AFP>400μg/L.
Estimated life expectancy of ≥12 weeks.
Female subjects of c [...]
Secondary endpointsdetails revised at 1 of 10 entries
Study description-51 characters
[...] y.
This study primarily evaluates the impact of iparomlimab combined withand tuvonralimab (QL1706) as preoperative neoadjuvant therapy on recurrence-free surv [...]
Enrolled patients will receive a single dose of iparomlimab/ and tuvonralimab within one week prior to surgery, followed by one session of transarterial chemoembolization (TACE) and six cycles of iparomlimab/ and tuvonralimab therapy postoperatively.